Prospects for a T-cell receptor vaccination against myasthenia gravis

Expert Review of Vaccines

Volumn 4, Issue 4, 2005, Pages 473-492

  Cohen Kaminsky, Sylvia ^a,b   Jambou, Florence ^b  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Autoimmune disease; Autoreactive T cells; Combined therapies; Immunoregulation; Myasthenia gravis; Pathogenic; T cell receptor; TCR peptide; TCR vaccine; Thymectomy

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CD8 ANTIGEN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; CYCLOSPORIN; CYTOKINE; GLUCOCORTICOID; HLA DR3 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; IR 103; IR 208; IR 501; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROVAX; PREDNISOLONE; PYRIDOSTIGMINE; RAVAX; REIMMUNE; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR VACCINE; TOVAXIN; UNCLASSIFIED DRUG; VACCINE; ZORCELL;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CATARACT; CLINICAL TRIAL; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; IMMUNOGENICITY; IMMUNOREGULATION; INFECTION SENSITIVITY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; OSTEOPOROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE; THYMECTOMY; VACCINATION; VACCINE PRODUCTION; WEIGHT GAIN;

ANIMALS; HUMANS; MYASTHENIA GRAVIS; RECEPTORS, ANTIGEN, T-CELL; VACCINES;

EID: 24744467402     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.4.473     Document Type: Review

References (124)

1. Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 357, 2122-2128 (2001). Recent review on all aspects of myasthenia gravis (MG), including treatments.
2. Vincent A. Unraveling the pathogenesis of myasthenia gravis. Natl Rev. Immunol. 2, 797-804 (2002). Recent review on pathogenesis of MG.
3. Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve 23, 453-477 (2000). Excellent review on the muscle nicotinic acetlycholine receptor autoantigen and its role in MG.
4. Drachman DB. Myasthenia gravis. In: The Autoimmune Diseases. Rose NR, Mackay IP (Eds), San Diego, CA, USA. 637-662 (1998). Good review on the pathogenesis of MG, antibody action and disease symptoms.
5. Melms A, Chrestel S, Schalke BC et al. Autoimmune T-lymphocytes in myasthenia gravis. Determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J. Clin. Invest. 83, 785-790 (1989).
6. Hohlfeld R, Toyka KV, Heininger K, Grosse-Wilde H, Kalies I. Autoimmune human T-lymphocytes specific for acetylcholine receptor. Nature 310, 244-246 (1984). One of the first papers indicating that anti-AChR antibodies are produced under the control of T-cells.
7. Giraud M, Beaurain G, Eymard B, Tranchant C, Gajdos P, Garchon HJ. Genetic control of autoantibody expression in autoimmune myasthenia gravis: role of the self-antigen and of HLA-linked loci. Genes Immun. 5, 398-404 (2004).
8. Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin. Neurol. 24, 125-133 (2004). Review on seronegative MG, a clinical subgroup of MG patients with diagnosis problems.
9. Vincent A, Bowen J, Newsom-Davis J, McConville J. Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets. Lancet Neurol. 2, 99-106 (2003). Excellent review on the pathogenesis of MG clinical subgroups, with a special focus on all aspects of seronegative MG.
10. Liyanage Y, Hoch W, Beeson D, Vincent A. The agrin/muscle-specific kinase pathway: new targets for autoimmune and genetic disorders at the neuromuscular junction. Muscle Nerve 25, 4-16 (2002).
11. Lindstrom J. Is 'seronegative' MG explained by autoantibodies to MuSK? Neurology 62, 1920-1921 (2004).
12. Berrih-Aknin S, Cohen-Kaminsky S, Neumann D et al. Cellular aspects of myasthenia gravis. Immunol. Res. 7, 189-199 (1988).
13. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum. Pathol. 9, 495-515 (1978). One of the first articles describing the features of thymic hyperplasia in MG.
14. Vincent A. Aetiological factors in the development of myasthenia gravis. Adv. Neuroimmunol. 4, 355-371 (1994). Review on etiologic aspects of MG, including the role of the thymus.
15. Willcox N. Myasthenia Gravis. Curr. Opin. Immunol. 5, 910-917 (1993). Describes the features of thymic hyperplasia in MG.
16. Salmon AM, Bruand C, Cardona A, Changeux JP, Berrih-Aknin S. An acetylcholine receptor α subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J. Clin. Invest. 101, 2340-2350 (1998). Excellent article attempting to understand the role of AChR expression in different thymic T-cell compartments.
17. Levinson AI, Wheatley LM. The thymus and the pathogenesis of myasthenia gravis. Clin. Immunol. Immunopathol. 78, 1-5 (1996). Role of the thymus in MG.
18. Wakkach A, Guyon T, Bruand C, Tzartos S, Cohen-Kaminsky S, Berrih-Aknin S. Expression of acetylcholine receptor genes in human thymic epithelial cells: implications for myasthenia gravis. J. Immunol. 157, 3752-3760 (1996).
19. Melms A, Schalke BC, Kirchner T, Muller-Hermelink HK, Albert E, Wekerle H. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. J. Clin. Invest. 81, 902-908 (1988). Isolation of autoreactive T-lymphocytes in the thymus of MG patients.
20. Truffault F, Cohen-Kaminsky S, Khalil I, Levasseur P, Berrih-Aknin S. Altered intrathymic T-cell repertoire in human myasthenia gravis. Ann. Neurol. 41, 731-741 (1997). One of the first studies to provide evidence of a biased T-cell repertoire in the MG thymus.
21. Moulian N, Bidault J, Truffault F, Yamamoto AM, Levasseur P, Berrih-Aknin S. Thymocyte Fas expression is dysregulated in myasthenia gravis patients with anti-acetylcholine receptor antibody. Blood 89, 3287-3295 (1997).
22. Sommer N, Willcox N, Harcourt GC, Newsom-Davis J. Myasthenic thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T-cells. Ann. Neurol. 28, 312-319 (1990). Evidence of autoreactive T-lymphocytes in the thymus of MG patients.
23. Fujii Y, Monden Y, Nakahara K, Hashimoto J, Kawashima Y. Antibody to acetylcholine receptor in myasthenia gravis: production by lymphocytes from thymus or thymoma. Neurology 34, 1182-1186 (1984). First evidence of autoantibody production by thymic cells.
24. Leprince C, Cohen-Kaminsky S, Berrih-Aknin S et al. Thymic B-cells from myasthenia gravis patients are activated B-cells. Phenotypic and functional analysis. J. Immunol. 145, 2115-2122 (1990). Comprehensive study on the phenotype, activation status and functional role in autoantibody production.
25. Berrih-Aknin S, Morel E, Raimond F et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann. NY Acad. Sci. 505, 50-70 (1987). Role of the thymus in a large series of MG patients, with classification of the patients on the basis of thymic phenotype.
26. Le Brigand H, Levasseur P, Miranda AR, Gaud C, Wojakowski I. Surgical treatment of myasthenia by thymectomy. A report on 248 cases. Sem. Hop. 56, 1502-1505 (1980). Clinical effect of thymectomy in large series of MG patients.
27. Molnar J, Szobor A. Myasthenia gravis: effect of thymectomy in 425 patients. A 15-year experience. Eur. J. Cardiothorac. Surg. 4, 8-14 (1990). Clinical effect of thymectomy in large series of MG patients.
28. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55, 7-15 (2000).
29. Jaretzki A, Barohn RJ, Ernstoff RM et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann. Thorac. Surg. 70, 327-334 (2000). Current view and guidelines for the indication of thymectomy in MG.
30. Phillips LH. The epidemiology of myasthenia gravis. Semin. Neurol. 24, 17-20 (2004). Recent review on the epidemiology of MG.
31. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain 123(Pt. 4), 665-676 (2000).
32. Grob D. Natural history of myasthenia gravis. In: Myasthenia Gravis and Myasthenic Disorders. Engel AG (Ed.) Oxford, UK. 131-145 (1999).
33. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 61, 1652-1661 (2003). Recent review on the current treatments of MG.
34. Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56, 97-99 (2001).
35. Drachman DB. Immunotherapy in neuromuscular disorders: current and future strategies. Muscle Nerve 19, 1239-1251 (1996).
36. Ferrero B, Durelli L. High-dose intravenous immunoglobulin G treatment of myasthenia gravis. Neurol. Sci. 23(Suppl. 1), S9-S24 (2002).
37. Antozzi C. Myasthenia gravis and myasthenic syndrome. Neurol. Sci. 24(Suppl.4), S260-S263 (2003). Recent review on the current treatments of MG, and discussion on the indication of intravenous human immunoglobulin (Ig) and plasmapheresis.
38. Engel AG. Congenital Myasthenic disorders. In: Myasthenis Gravis and Myasthenic Disorders. Engel AG (Ed), Oxford, 251-297 (1999).
39. Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenia syndrome. Semin. Neurol. 23, 191-198 (2003). Recent review on the current treatments of MG and the therapeutic option in each patient subgroup.
40. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann. Neurol. 41, 789-796 (1997).
41. Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve 22, 1479-1497 (1999).
42. Keesey JC. A history of treatments for myasthenia gravis. Semin. Neurol. 24, 5-16 (2004). Historic perspective on treatments in MG.
43. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin. Immunol. 94, 75-87 (2000). Review on the use of animal models of MG to understand pathogenesis and evaluate treatments.
44. Tzartos SJ, Barkas T, Cung MT et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163, 89-120 (1998). Excellent review on the B-cell epitopes and B-cell repertoire of AChR.
45. Berrih-Aknin S, Cohen-Kaminsky S, Lepage V, Neumann D, Bach JF, Fuchs S. T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J Autoimmun. 4, 137-153 (1991).
46. Protti MP, Manfredi AA, Horton RM, Bellone M, Conti-Tronconi BM. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today. 14, 363-368 (1993). Review on the diversity of T-cell epitopes in MG.
47. Weiner HL. Induction of oral tolerance to the acetylcholine receptor for treatment of myasthenia gravis. J. Clin. Invest. 104, 1667-1668 (1999).
48. Im SH, Barchan D, Fuchs S, Souroujon MC. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J. Clin. Invest. 104, 1723-1730 (1999). Evidence of the beneficial effect of an oral treatment with recombinant acetylcholine receptor in experimental autoimmune MG.
49. Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152, 112-120 (2004). Use of syngeneic AChR fragments for oral tolerance in rats.
50. Pachner AR. Antigen-specific immunotherapy in myasthenia gravis: failed promise and new hope. J. Neuroimmunol. 152, vii-viii (2004). Use of syngeneic AChR fragments for oral tolerance in rats.
51. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit. Rev. Immunol. 20, 1-16 (2000).
52. Faria AM, Weiner HL. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol 73, 153-264 (1999).
53. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167-1175 (2000). Clinical trial showing that treatment with autoantigen fragments can be harmful.
54. Weathington NM, Blalock JE. Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network. Expert Rev. Vaccines 2, 61-73 (2003). Review of the use of complementary autoantigen peptides in the treatment of autoimmune diseases.
55. Pendergraft WF III, Preston GA, Shah RR et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nature Med. 10, 72-79 (2004). Suggests that a complementary peptide can initiate an autoimmune disease.
56. Vandenbark AA, Hashim GA, Offner H. T-cell receptor peptides in treatment of autoimmune disease: rationale and potential. J Neurosci. Res. 43, 391-402 (1996). Review on the potential of T-cell receptor (TCR) peptide therapy in MG, discussing the different possibilities for the choice of the therapeutic peptide.
57. + T-cell subsets of myasthenia gravis patients: a role for superantigen(s)? Mol. Med. 2, 452-459 (1996). Evidence of a diverse T-cell repertoire in MG.
58. Mantegazza R, Oksenberg JR, Baggi F et al. Increased incidence of certain TCR and HLA genes associated with myasthenia gravis in Italians. J. Autoimmun. 3, 431-440 (1990). Evidence of a diverse T-cell repertoire in MG.
59. Grunewald J, Ahlberg R, LefVert AK, DerSimonian H, Wigzell H, Janson CH. Abnormal T-cell expansion and V-gene usage in myasthenia gravis patients. Scand. J. Immunol. 34, 161-168 (1991). Evidence of a diverse T-cell repertoire in MG.
60. Willcox N, Baggi F, Batocchi AP et al. Approaches for studying the pathogenic T-cells in autoimmune patients. Ann. NY Acad. Sci. 681, 219-237 (1993).
61. Melms A, Oksenberg JR, Malcherek G et al. T-cell receptor gene usage of acetylcholine receptor-specific T-helper cells. Ann. NY Acad. Sci. 681, 313-314 (1993). Evidence of a diverse T-cell repertoire in MG.
62. + T-cells in myasthenia gravis patients have individual, but restricted TCR V beta usage. Ann. NY Acad. Sci. 841, 324-328 (1998). Evidence of a diverse T-cell repertoire in MG.
63. Infante AJ, Baillargeon J, Kraig E et al. Evidence of a diverse T-cell receptor repertoire for acetylcholine receptor, the autoantigen of myasthenia gravis. J. Autoimmun. 21, 167-174 (2003).
64. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nature Rev. Immunol. 2, 85-95 (2002).
65. Aissaoui A, Klingel-Schmitt I, Couderc J et al. Prevention of autoimmune attack by targeting specific T-cell receptor in a SCID mice model of myasthenia gravis. Ann. Neurol. 46, 559-567 (1999). Demonstrates the pathogenicity of a dominant T-cell population from the thymus of MG patients in a humanized severe combined immune deficient (SCID) mouse model.
66. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103, 579-601 (1980). Human leukocyte antigen (HLA)-DR3 association in MG patients.
67. Vieira ML, Caillat-Zucman S, Gajdos P, Cohen-Kaminsky S, Casteur A, Bach JF. Identification by genomic typing of non-DR3 HLA class II genes associated with myasthenia gravis. J. Neuroimmunol. 47, 115-122 (1993).
68. Jambou F, Zhang W, Menestrier M et al. Circulating regulatory anti-TCR antibodies in patients with myasthenia gravis. J. Clin. Invest. 112, 265-274 (2003). Demonstration of the regulatory and protective role of spontaneous anti-TCR antibodies targeting a dominant T-cell population in MG.
69. Jambou F, Menestrier M, Klingel-Schmitt I et al. Rationale for a T-cell receptor peptide therapy in Myasthenia Gravis. Ann. NY Acad. Sci. USA. 988, 320-323 (2003).
70. Jambou F, Cohen-Kaminsky S. Immunoregulation by Vβ specific antibodies in myasthenia gravis: mining physiological T-cell homeostasis for TCR specific therapy. Cell Mol. Biol, (Noisy-legrand) 181-192 (2003). Review on the physiologic and regulatory role of anti-TCR antibodies in adaptive immunity and autoimmunity.
71. Kahn CR, McIntosh KR, Drachman DB. T-cell vaccination in experimental myasthenia gravis: a double-edged sword. J. Autoimmun. 3, 659-669 (1990). One of the first studies on T-cell vaccination in MG.
72. Sela M, Arnon R, Schechter B. Therapeutic vaccines: realities of today and hopes for the future. Drug Discov. Today. 7, 664-673 (2002). Review on the concept of therapeutic as opposed to prophylactic preventive vaccines.
73. Cohen IR. T-cell vaccination for autoimmune disease: a panorama. Vaccine 20, 706-710 (2001). Good review on T-cell vaccination in autoimmune diseases: history, rationale, state of the art and mechanisms of action of T-cell vaccination.
74. Kumar V, Coulsell E, Ober B, Hubbard G, Sercarz E, Ward ES. Recombinant T-cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis: dose effects and involvement of both CD4 and CD8 T-cells. J. Immunol 159, 5150-5156 (1997). TCR vaccination using recombinant fragments in protection (prevention and reversal) of autoimmune encephalomyelitis (EAE).
75. Offner H, Adlard K, Bebo BF Jr et al. Vaccination with BV8S2 protein amplifies TCR-specific regulation and protection against experimental autoimmune encephalomyelitis in TCR BV8S2 transgenic mice. J. Immunol. 161, 2178-2186 (1998). TCR vaccination using recombinant fragments in protection (prevention and reversal) of EAE.
76. Waisman A, Ruiz PJ, Hirschberg DL et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 Immunity Nature Med. 2, 899-905 (1996). Use of genetic vaccination in prevention of EAE.
77. Kumar V, Sercarz E. Genetic vaccination: the advantages of going naked. Nature Med 2, 857-859 (1996). Review of genetic vaccination.
78. Matsumoto Y, Jee Y, Sugisaki M. Successful TCR-based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR. J. Immunol. 164, 2248-2254 (2000).
79. Braciak TA, Pedersen B, Chin J et al. Protection against experimental autoimmune encephalomyelitis generated by a recombinant adenovirus vector expressing the Vξ 8.2 TCR is disrupted by coadministration with vectors expressing either IL-4 or -10. J. Immunol. 170, 765-774 (2003).
80. Vandenbark AA, Morgan E, Bartholomew R et al. TCR peptide therapy in human autoimmune diseases. Neurochem. Res. 26, 713-730 (2001). Comprehensive review on 14 clinical trials (completed or ongoing) using TCR peptides for the treatment of autoimmune diseases mulitple sclerosis (MS), rheumatoid arthritis (RA) and psoriasis in large numbers of patients.
81. Vandenbark AA, Chou YK, Whitham R et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nature Med. 2, 1109-1115 (1996). First published double-blind trial using TCR peptide vaccine in MS.
82. Hellings N, Raus J, Stinissen P. T-cell vaccination in multiple sclerosis: update on clinical application and mode of action. Autoimmun. Rev. 3, 267-275 (2004). T-cell vaccination in MS, presenting all the completed and ongoing trials.
83. Kumar V, Sercarz E, Zhang J, Cohen I. T-cell vaccination: from basics to the clinic. Trends Immunol. 22, 539-540 (2001).
84. Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis. Expert Rev. Vaccines 1, 285-292 (2002). Review on T-cell vaccination in EAE and MS.
85. Cohen IR. Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination. Diabetologia 45, 1468-1474 (2002).
86. Lambert SL, Okada CY, Levy R. TCR vaccines against a murine T-cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J. Immunol. 172, 929-936 (2004). Demonstration of a primary role of anti-TCR antibodies in TCR vaccine against a murine lymphoma. The mechanisms and cell population involved are delineated using several knockout mouse models.
87. Husband AJ, Bao S, McClure SJ, Emery DL, Ramsay AJ. Antigen delivery strategies for mucosal vaccines. Int. J. Parasitol. 26, 825-834 (1996).
88. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 14, 666-672 (2002).
89. Bourdette DN, Whitham RH, Chou YK et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ 5.2 and Vβ 6.1 CDR2 peptides. J. Immunol. 152, 2510-2519 (1994). Preclinical data to assess immunogenicity of TCR peptide vaccines in MS patients.
90. Chou YK, Morrison WJ, Weinberg AD et al. Immunity to TCR peptides in multiple sclerosis. II. T-cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides. J. Immunol. 152, 2520-2529 (1994). Preclinical data to assess immunogenicity of TCR peptide vaccines in MS patients.
91. Haqqi TM, Qu XM, Anthony D, Ma J, Sy MS. Immunization with T-cell receptor V beta chain peptides deletes pathogenic T-cells and prevents the induction of collagen-induced arthritis in mice. J. Clin. Invest. 97, 2849-2858 (1996). Demonstration of the regulation of anti-TCR antibodies in TCR vaccination.
92. Moreland LW, Heck LW Jr, Koopman WJ et al. V beta 17 T-cell receptor peptide vaccination in rheumatoid arthritis: results of Phase I dose escalation study. J. Rheumatol. 23, 1353-1362 (1996).
93. Bridges SL Jr, Moreland LW. T-cell receptor peptide vaccination in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24, 641-650 (1998).
94. Garren H, Ruiz PJ, Watkins TA et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15, 15-22 (2001).
95. Kumar V, Sercarz E. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol. Rev. 182, 113-121 (2001). Excellent review of the innate T-T circuitry involving TCR recognition, which is thought to be boosted after TCR vaccination.
96. Sercarz E, Maverakis E, van den Elzen P, Madakamutil L, Kumar V. Seven surprises in the TCR-centred regulation of immune responsiveness in an autoimmune system. Novartis Found. Symp. 252, 165-171 (2003). Excellent review of the innate T-T circuitry involving TCR recognition, which is thought to be boosted after TCR vaccination.
97. Madakamutil LT, Maricic I, Sercarz E, Kumar V. Regulatory T-cells control autoimmunity in vivo by inducing apoptotic depletion of activated pathogenic lymphocytes. J. Immunol. 170, 2985-2992 (2003). First evidence of in vivo apoptotic depletion mediated by regulatory T-cells in the control of autoimmunity.
98. Hermans G, Denzer U, Lohse A, Raus J, Stinissen P. Cellular and humoral immune responses against autoreactive T-cells in multiple sclerosis patients after T-cell vaccination. J. Autoimmun. 13, 233-246 (1999).
99. Honda A, Ametani A, Matsumoto T et al. Vaccination with an immunodominant peptide of bovine Type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int. Immunol. 16, 737-745 (2004). Indicates that during tolerance induction, an effective anti-TCR response is mounted naturally and regulates the pathogenic autoimmune response. This indicates that probably common T-T circuitry and mechanisms are involved in tolerance induction to antigen and T-cell and TCR vaccination.
100. Elias D, Tikochinski Y, Frankel G, Cohen IR. Regulation of NOD mouse autoimmune diabetes by T-cells that recognize a TCR CDR3 peptide. Int. Immunol. 11, 957-966 (1999). Indicates that during tolerance induction, an effective anti-TCR response is mounted naturally and regulates the pathogenic autoimmune response. This indicates that probably common T-T circuitry and mechanisms are involved in tolerance induction to antigen and T-cell and TCR vaccination.
101. + T-cells, among which are found anti-TCR T-cells.
102. Vandenbark AA, Hicks K, Tsaknaridis L et al. Regulation of autoimmunity with TCR peptides: latest breakthroughs. 6th International Symposium on the Immunotherapy of the Rheumatic Disesases. Cyprus (2002).
103. + T-cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105, 735-741 (2005). Analysis of the T-regulatory (Treg) cells in the MG thymus, indicating that these cells are defective.
104. Kumar V. Homeostatic control of immunity by TCR peptide-specific Tregs. J. Clin. Invest. 114, 1222-1226 (2004). Demonstration of the existence of anti-TCR T-cells in Treg cells in EAE.
105. + T-cells for self-T-cell receptor determinants. J. Neurosci. Res. 76, 129-140 (2004). Demonstrates that Treg cells are specific for TCR determinants.
106. Liu HY, Buenafe AC, Matejuk A et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70, 238-248 (2002).
107. + regulatory T-cell compartment. J. Immunol. 173, 2227-2230 (2004).
108. Offner H, Adlard K, Zamora A, Vandenbark AA. Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J. Clin. Invest. 105, 1465-1472 (2000).
109. Herkel J, Brunner S, Meyer zum Buschenfelde KH, Lohse AW. Humoral mechanisms in T-cell vaccination: induction and functional characterization of antilymphocytic autoantibodies. J. Autoimmun. 10, 137-146 (1997). Humoral mechanisms and anti-idiotypic antibodies induced by T-cell vaccination.
110. Hong J, Zang YC, Tejada-Simon MV et al. Reactivity and regulatory properties of human anti-idiotypic antibodies induced by T-cell vaccination. J. Immunol. 165, 6858-6864 (2000). Humoral mechanisms and anti-idiotypic antibodies induced by T-cell vaccination.
111. Billiau A, Matthys P. Modes of action of Freunds adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70, 849-860 (2001).
112. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 2, 305-315 (2003).
113. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223-243 (1997).
114. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun. Rev. 2, 119-125 (2003). Recent review on epidemiology of the most well characterized autoimmune diseases.
115. Morgan EE, Nardo CJ, Diveley JP et al. Vaccination with a CDR2 BV6S2/6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. J. Neurosci. Res. 64, 298-301 (2001).
116. Moreland LW, Morgan EE, Adamson TC III et al. T-cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vβ3, Vβ14, and Vβ17 peptides. Arthritis Rheum. 41, 1919-1929 (1998). Use of TCR peptide cocktails as vaccines in RA.
117. Pannetier C, Cochet M, Darche S, Casrouge A, Zoller M, Kourilsky P. The sizes of the CDR3 hypervariable regions of the murine T-cell receptor β chains vary as a function of the recombined germ-line segments. Proc. Natl Acad. Sci. USA 90, 4319-4323 (1993).
118. Pasqual N, Gallagher M, Aude-Garcia C et al. Quantitative and qualitative changes in V-J α rearrangements during mouse thymocytes differentiation: implication for a limited T-cell receptor α chain repertoire. J. Exp. Med. 196, 1163-1173 (2002). New powerful technique to analyze exhaustively the T-cell repertoire of all TCR chains, which can better define an immune signature and the dominant TCRs in each patient.
119. Muraro PA, Jacobsen M, Necker A et al. Rapid identification of local T-cell expansion in inflammatory organ diseases by flow cytometric T-cell receptor Vβ analysis. J. Immunol. Methods 246, 131-143 (2000).
120. Guillet M, Sebille F, Soulillou J. TCR usage in naive and committed alloreactive cells: implications for the understanding of TCR biases in transplantation. Curr. Opin. Immunol. 13, 566-571 (2001).
121. Steinman L. Despite epitope spreading in the pathogenesis of autoimmune disease, highly restricted approaches to immune therapy may still succeed (with a hedge on this bet). J. Autoimmun. 14, 278-282 (2000).
122. Vincent A, Willcox N, Hill M, Curnow J, MacLennan C, Beeson D. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol. Rev. 164, 157-168 (1998). Review on the contribution of determinant spreading to MG pathogenesis.
123. Xu L, Villain M, Galin FS, Araga S, Blalock JE. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T-cells. Cell Immunol. 208, 107-114 (2001).
124. Villinger F. Cytokines as clinical adjuvants: how far are we? Expert Rev. Vaccines 2, 317-326 (2003).